RE:RE:Q: Still dosing? They chose the latter option as Resverlogix stated at and since the AGM. No reason to suspect poor design or desperation. It's actually a good thing from a safety, efficacy and statistical viewpoint to choose the adaptive path they chose.
Thank you Bear, I think this is exactly the answer i'm looking for!
sometimes quite difficult to interpret each company communiqu, don't know why they need to be so cryptic. i'm a layperon, so maybe its not important for me to fully grasp, which is why i tend to let mr market (and now Bear) interpret for me. Mr M doesn't seem terribly impressed so far and i gues his reaction and interpretation trumps mine...
anyways, thanks for confirming, that was one of my interpretations: good design, maybe 4%+ wiggle room, which might counteract drop outs, or people not taking the drug, or ...
happy easter everyone!